Treatment of sialorrhoea in patients with Parkinson??s disease: best current evidence

Molloy, Luke

doi:10.1097/01.wco.0000280411.57836.aa

Cited by 35 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with anticholinergics may be helpful, but they are frequently associated with side effects. 819 Botulinum toxin has emerged as the most effective treatment for sialorrhea in PD. Double-blind studies have demonstrated reduced drooling and reduced disability with both botulinum toxin A and B.…”

Section: Impulse Dyscontrol and Dopamine Dysregulation Disordersmentioning

confidence: 99%

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow¹,

Stern²,

Sethi³

2009

Neurology

760

658

View full text Add to dashboard Cite

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many as 1-2% of persons aged 60 years and older. With the aging of the population, the frequency of PD is expected to increase dramatically in the coming decades. Current therapy is largely based on a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However, chronic treatment is associated with the development of motor complications, and the disease is inexorably progressive. Further, advancing disease is associated with the emergence of features such as freezing, falling, and dementia which are not adequately controlled with dopaminergic therapies. Indeed, it is now appreciated that these nondopaminergic features are common and the major source of disability for patients with advanced disease. Many different therapeutic agents and treatment strategies have been evaluated over the past several years to try and address these unmet medical needs, and many promising approaches are currently being tested in the laboratory and in the clinic. As a result, there are now many new therapies and strategic approaches available for the treatment of the different stages of PD, with which the treating physician must be familiar in order to provide patients with optimal care. This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials. It is intended to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of the different approaches. 1 PD is the second most common neurodegenerative disorder, with an average age at onset of about 60 years. An estimated 5 million people throughout the world have PD, with 1 million individuals each in the United States and in Europe with the disorder. PD affects approximately 0.3% of the population and 1% to 2% of those older than 60 years.2 With the aging of the population and the substantial increase in the number of at-risk individuals older than 60 years, it is anticipated that the prevalence of PD will increase dramatically in the coming decades.

show abstract

Section: Impulse Dyscontrol and Dopamine Dysregulation Disordersmentioning

confidence: 99%

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow¹,

Stern²,

Sethi³

2009

Neurology

760

658

View full text Add to dashboard Cite

show abstract

“…Siyalore için yap›lan BT enjeksiyonlar›n›n yan etkileri aras›nda a¤r›, lokal hematom, tükürük kanal›nda tafl oluflumu, tükürük bezinde enfeksiyon, a¤›z kurulu¤u, disfaji ve çene kaslar›nda güçsüzlük say›labilir (48,49). Amiyotrofik lateral skleroz hastalar›nda BT uygulamas› yaparken özellikle disfaji ve çene kaslar›nda güçsüzlü¤ün ortaya ç›kabilme ihtimali göz önüne al›nmal›d›r.…”

Section: Siyaloreunclassified

Hipersekretuvar Bozukluklar ve Botulinum Toksini

Hanağası¹

2011

Npa

View full text Add to dashboard Cite

ÖZETSalg› bezleri ile ilgili bozukluklar›n tedavisinde botulinum toksini kullan›m›n›n s›kl›¤› son y›llarda giderek artmaktad›r. Hiperhidrozis vücut ›s›s›n›n normale dönmesinin ötesinde afl›r› terleme olarak tan›mlan›r. Siyalore pek çok nörodejeneratif hastal›kta s›k görülen bir semptomdur. Hiperhidrozis ve siyalore fiziksel ve psikososyal malüliyet yaratabilirler. Pek çok bildiri hipersekretuvar bozukluklarda botulinum toksini kullan›m›n›n az yan etki ile olumlu sonuçlar al›nd›¤›n› göstermifltir. (Nöropsikiyatri Arflivi 2010; 47 Özel Say›: 48-51) Anahtar kelimeler: Botulinum toksini, hiperhidrozis, siyalore, Frey sendromu, afl›r› lakrimasyon, kronik rinit ABSTRACT An increase in the popularity of botulinum toxin for treatment of salivary gland disorders has been observed in recent years. Hyperhidrosis is characterized by excessive sweat production, beyond the required quantity to return increased body temperature to normal. Sialorrhoea is a common symptom in many neurodegenerative disorders. Hyperhidrosis and sialorrhea can cause both physical and psychosocial disability. Many reports on the use of botulinum toxin in hypersecretory disorders have shown favourable results with minimal side effects. (Archives of Neuropsychiatry 2010; 47 Supplement: 48-51)

show abstract

“…Ce symptôme, à l'origine d'une morbidité psychosociale et physique, est retrouvé chez l'adulte dans les atteintes neurologiques telles que la sclérose latérale amyo-DOI de l'article original : 10 [4]). L'utilisation des anticholinergiques par voie systémique [2], l'atropine et la scopolamine, est efficace mais contreindiquée en cas de glaucome, d'uropathie obstructive et de myasthénie. Ces traitements disponibles sous forme de patchs de scopolamine ou de gouttes sublinguales d'atropine, sont d'efficacité reconnue mais limitée du fait des difficultés d'observance.…”

Section: Introductionunclassified